Shivom Partners With Lifebit

Blockchain genomics pioneer and AI data analysis firm will provide pharmaceutical organisations and life science users with comprehensive reporting through a library of pipelines

London, United Kingdom – 11 December 2018 – Shivom, the blockchain genomics platform that is powering personalized healthcare, has partnered with Lifebit, the AI-powered DNA-analysis firm, to give users unprecedented reporting capabilities for DNA data analysis.

The partnership will mean that immediate Genome Wide Association Study (GWAS) analysis is possible, with no specialist knowledge or in-house data scientist required. It also means that users can access a library of pipelines (ready built softwares that are used for analysis) and an AI-powered toolkit for analysing the data in a way that is far more scalable than other solutions.

Another aspect that makes the Shivom platform superior to other genomics platforms is that it will give pharmaceutical organisations and life science users the ability to access real-time analysis whenever they need it with no waiting time, no application process for accessing the data and deadlines or cut off dates that restrict their access.

“Through this partnership with Lifebit, we are providing enterprise users with the tools they need to find the right patients for their clinical trials more easily and more accurately than is possible through other solutions. Not only that, it brings AI into GWAS analysis in a way that hasn’t been seen before,” said Dr Axel Schumacher, Co-Founder and Chief Scientific of Shivom.

The use of genomics platforms to improve rare disease treatment has increased in recent months, with 23andMe partnering with GlaxoSmithKline to develop drugs for Parkinson’s. However, the Shivom Lifebit partnership demonstrates a major leap forward in this area because it adds AI and Machine Learning capabilities to the identification of potential patients.

To do this, users will be able to access a library of pipelines within the Shivom platform. These include preset Shivom pipelines, those created through open source software and any that an enterprise chooses to develop using Github and DOCKER services.

“Our partnership with Shivom will allow us to combine unique datasets with a level of analysis automation and insight generation that has never been seen before on a genomics platform,” said Dr. Maria Chatzou, co-founder and CEO of Lifebit. “In this way, scientists and doctors will be able to get all the benefits of this rich database without the need to rely on a data scientist for help. On the other hand, still ensuring that the individuals that have provided data to Shivom are given a level of security and control only a state-of-art blockchain technology can offer.”

The partnership with Lifebit comes with the Shivom platform having already been released in alpha. The full launch of the platform is expected in Q1 2019.


Media Contact:
Frances Wells
Cryptoland PR
US: 866–586–5603
UK: +44 020 3908 5686

About Shivom:
Shivom is powering the next era of genomics through blockchain technology – protecting identity, personalizing healthcare and transforming lives. For the first time ever, a precision medicine ecosystem will offer an open web-marketplace for other providers to add not only genomics information, but also analytics and associated apps and services to drive personalized medicine. Shivom intends to extend its services to form a global network of associated laboratories and research centres, as well as genetic counsellors and other relevant services.  For further information, please visit:

About Lifebit
Lifebit is building a cloud-based cognitive system that can reason about DNA data like humans do. This offers researchers/R&D professionals, and their corresponding organisations (ie. pharmas), a highly scalable, modular and reproducible system that automates the analysis processes, learns from the data and provides actionable insights. For further information, please visit:

Shivom Announces Token Buyback Plans

SHIVOM Announces Token Buyback Plans in Preparation for Platform Rollout in 2019
SHIVOM Announces Token Buyback Plans in Preparation for Platform Rollout in 2019

Shivom is pleased to announce its plans to buyback up to 30 million OMX tokens or approximately 5% of current circulating supply in preparation for Shivom’s beta platform release plans in 2019. Beyond simply removing some OMX from current market conditions, Shivom plans to allocate the repurchased OMX tokens exclusively for incentivizing early adopters and driving community engagement on the Shivom platform.

According to Shivom CEO Henry Ines, “the buyback program is part of a multi-prong strategy to accelerate growth of the Shivom ecosystem, onboard new users, drive community awareness and engagement and ultimately to further enhance the value of the Shivom platform and the OMX token ecosystem.”

The repurchased tokens will be utilized to provide incentives and benefits particularly to new users, who upload their existing genomic data file on to Shivom’s secure platform and for those who purchase Shivom-branded kits and services in 2019. The buyback program will commence on 01 November 2018 and is expected to conclude by 31 January 2019.

In the interim period, Shivom also plans to release its ‘alpha’ platform on a limited basis for early testing and feedback purposes. The company in parallel also continues to advance its clinical R&D and pilot projects.

Stay tuned for more exciting announcements!

For more information and latest updates please join our Telegram channel here

Blockchain to Combat Type 2 Diabetes Epidemic in India

Blockchain to Combat Type 2 Diabetes Epidemic in India
Blockchain to Combat Type 2 Diabetes Epidemic in India

Genomics pioneer Shivom hopes to transform diagnosis and treatment of a disease that’s pervasive in the country

London, UK — 25 September 2018: A pioneering diabetes pilot to collect, sequence and analyze DNA in India, with the aim of using the data for improved diagnosis and treatment of a disease that is devastating the country.

Genomics and precision medicine startup Shivom is working with diagnostic partner Genetic Technologies Limited (GTG; ASX:GTG; NASDAQ:GENE) with the goal of finding unique genetic markers specific to Indian subpopulations that may help explain why the country has one of the highest rising prevalences of the type 2 diabetes in the world. Diabetes is a chronic, metabolic disease characterised by elevated levels of blood glucose. Over time it leads to serious damage to the heart, blood vessels, eyes, kidneys and nerves.

Incidences of type 2 diabetes in India have more than quadrupled in 35 years, with communities developing the disease at younger ages and at lower body weights than other populations. According to the World health Organization, around 72 million Indians have the disease.

The ground-breaking pilot involves thousands of patients and will start in the south-eastern state of Andhra Pradesh — some of whom have already been diagnosed with type 2 diabetes, and control participants who don’t have the disease.

The process will involve collecting saliva samples of the patients from which DNA will be extracted, analyzed and secured on Shivom’s blockchain-based genomics datahub. Shivom’s partner — diagnostics leader Genetic Technologies Limited — will help analyze the collected anonymous genomic-samples and data with the goal of developing a diagnostic SNP panel specific to the Indian population.

The pilot to help combat this epidemic in India, has caught the interest of U.S. TV. It’s launch and progress is being documented as part of the CNBC show, Advancements presented by actor Ted Danson.

Secure and anonymized

Patients’ data will remain absolutely confidential and secure on Shivom’s blockchain-based genomics datahub. However it will be easily shareable in anonymized form and interoperable across technological boundaries.

The patients will have control of their data at all time and can withdraw it from the database when they choose to. Participants are expected to receive health insights and benefits. In the future, they will have the option to be compensated for its use in trials.

Dr. Axel Schumacher, founding member and Chief Scientific Officer of Shivom, said: “Shivom and the province of Andhra Pradesh are working to usher in a new era of precision medicine that successfully leverages state-of-the-art technologies, latest scientific advancements in genomics and new economic models, something we have never seen before.

“These have the potential to revolutionize the way healthcare pilots are performed, empowering all people to better manage their wellness, avoid diabetes, and to be stakeholders in the future of healthcare.”

Recently, Shivom also announced a partnership with EMQT, working together to collect data on Sickle Cell Disease in Nigeria, Africa. Such partnerships are the building blocks in gathering diverse patient data in the global healthcare community and as securely as possible.

Organizations operating in the health and related sectors will be able to access information contained in Shivom’s data-hub once an individual chooses to release their DNA data.


Media Contact:
Sophie Smithers
Cryptoland PR
US: 866–586–5603
UK: +44 (0) 203 908 5565

About Shivom:
Shivom is a leading healthcare technology company focused on developing the world’s largest precision medicine data hub and healthcare services platform powered by blockchain technology. By leveraging the latest advancements in genomics, cryptography and cutting-edge machine learning algorithms, Shivom aims to democratize genomic sequencing in-order to provide individuals with a secure platform that automates their health and wellness.

To-date, Shivom has established multiple global relationships with blockchain companies such as SingularityNET, Spherity and Ocean Protocol to publicly-traded diagnostics companies and governments such as GTG Labs and the Government of the Indian State of Andhra Pradesh.

For more information, please visit:

Shivom’s Pact with Social Impact

Shivom’s Pact with Social Impact
Shivom’s Pact with Social Impact

We know the ability to collect and analyze a person’s DNA to identify and potentially treat inherited medical conditions is a relatively recent phenomenon in the spectrum of medical history. While genomic science and research (which represents the more complex interaction of genes and the environment vs. study of particular genes alone) is now at full-speed, ethical concerns and issues have followed a parallel track. As the field advanced, many experts inside and out of the scientific community have questioned how genetic data would be used and whether it would adequately inform the medical community towards the best ends possible for patients. For all intents, the community has accepted that genomic medicine can exponentially improve human health, but the conversation about its social impact continues.

In 2016, the National Institutes of Health (NIH) announced it would offer four new grants specifically to study the ethical, legal and social impact of genomic sciences through the National Human Genome Research Institute’s Center for Excellence. “The projects will examine the use of genomic information in the prevention and treatment of infectious diseases; genomic information privacy; communication about prenatal and newborn genomic testing results; and the impact of genomics in American Indian and Alaskan Native communities” in the United States. When you widen the genomic medicine lens globally, the issues become even more complex, bringing socioeconomics, politics and culture into the picture. The World Health Organization (WHO) has recognized the intersection of global health and genomic medicine since the 1950s (Gibbon, Kilshaw & Faulkner, 2017), and now reports that low to middle income countries account for 92 per cent of global burden of disease.

In part, concerns around genomic medicine globally involve how and where data is collected, how it is analyzed, and also how it contributes to prevention and treatment in equal measure across global communities. One step further is the core question of ownership — does the medical community or individual own the DNA data collected? Privacy concerns discourage contributors to the data pool, methods of generating this information tend to draw from limited populations, and weak compensation plans keep those intrigued from participating at all. These questions and concerns have helped shape Shivom’s mission of creating secure storage and collection of DNA data and giving data donors the absolute control to share their information with the global healthcare community. It is with well-established ethical and social issues in mind that Shivom aims its programs toward the advancement of global healthcare, applying its technology towards secure analysis of big data.

To create a truly positive impact on global health, you need to have access to big data. However, data samples are not created equal, and even many large sample pools do not contain significant contributions from under-represented communities that have a high incidence of a particular disease. This lack of data leaves these groups out of the equation, and by extent, leaves the problem unsolvable. To address this challenge, Shivom has begun the process of collecting samples of the most diverse data available by reaching some of the most remote areas of the world, particularly focusing on previously underrepresented populations. In more technologically advanced and developed societies, people can upload their own data on our platform. Ultimately, more DNA data leads to better biomarkers of disease, which creates more effective drugs for a wider range of patients and successful clinical trials. Pharmaceutical companies can make use of the DNA sequence sets to drive their R&D pipelines and develop successful and unique drugs based on individual genetic backgrounds.

By combining voluntary, in-the-field data collection with innovative technology and global focus, Shivom is committed to fulfilling its mission of advancing global healthcare in a socially responsible way. Reaching underrepresented communities, particularly many of those that make up the majority of global burden of disease is one of our top goals. We think it’s important to allow larger groups across socioeconomic categories to contribute and control their data because we believe that the positive social implications outweigh the negative — whether that be regarding the secure storage of data collected, the ethical use of data towards medical breakthroughs or simply an individual and physician’s knowledge of DNA markers that help inform them of the best prevention methods for certain medical conditions. Read more about the NIH’s take on the impacts of genomic medicine on global health.

Rounding Out 2018, Project Shivom Goes Into High Gear

Rounding Out 2018, Project Shivom Goes Into High Gear
Rounding Out 2018, Project Shivom Goes Into High Gear

As we enter the home stretch of 2018, Project Shivom celebrates an historic and successful ICO, expansion of our token exchange across four cryptocurrency platforms, and a restructured company leadership now helmed by CEO Henry Ines. Next, we look forward to exciting partnerships and projects that will help us fulfill our mission to protect patient identity, personalize healthcare and transform lives around the world. We are on the march to a new era in genomic science and precision medicine, from detection to delivery and anchored by unprecedented privacy.

One of the key challenges of successfully applying precision medicine in practice is the ability to properly integrate and interpret large amounts of genomic data to an accurate treatment. Of course, that involves both effective front-end collection of diverse data sets and then even more precise back-end analysis and application. The ability to properly interpret data is an ongoing challenge, particularly as there are not enough geneticists to do the job or the data that is collected often goes under or unutilized. Picture multiple highways funneling into one or two major roads — without the proper system, vehicles end up creating a bottleneck and then ultimately choose different roads altogether. This is the dissipation effect that prevents a solid connection between genomic and precision medicine. So, this takes time — to get the right people trained to analyze data, to get healthcare professionals to be able to understand and interpret the data, and then to have the right treatments available in a timely manner. During this time, data that is collected is stored — that brings up a whole other set of issues and security being the most significant one.

There is a recognition in the field that any new genomic science technology product must ultimately serve to make the collection to analysis road more effective, secure and able to more precisely connect patients with treatment. Shivom is in the midst of developing a platform that is broad, inclusive and focused on the healthcare needs of both large communities and individuals. As we’ve written previously, our goal is to utilize genomic data to better target individual treatments, alleviate specific diseases with high incidence in regions where it often goes undiagnosed, and improve the quality of healthcare worldwide. Most importantly, we are creating the building blocks to gather the most diverse patient data the global healthcare community has ever seen, and as securely as possible. But, a related focus is bridging the gap between collection and analysis, which we attempt to do with the application of AI technology.

In 2019, Project Shivom will begin sample data collection of sickle-cell disease bearers in Sub-Saharan Africa and those afflicted with type-2 diabetes in India. Both diseases, in which genetics plays a critical role, are ravaging susceptible populations in their respective regions. They are manageable with modern technology, but often go entirely undiagnosed, significantly worsening their impact on the individuals they afflict. Our partnerships will allow us to apply the most advanced, secure technology to collect patient data, sequence it, and analyze it. After we do this, users can share their unique set of genomic information with healthcare professionals and medical researchers. This will not only allow researchers to produce more advanced and affordable treatments, it will help them solve the particular issues that face marginalized communities that would otherwise go unstudied and untreated.

Our partnerships will play an integral role in helping to carry out our mission. In June, Project Shivom introduced two new partnerships that will help us further fuse blockchain and artificial intelligence to improve the quality of health for global citizens. The first, Our work with SingularityNET, will greatly increase our ability to offer personalized medical analytics by fusing our unmatched supply of data with their vast network of artificial intelligence solutions, allowing the medical world to solve problems with greater speed, certainty, and raw power than ever before. By bringing our powerful blockchain solution together with their potent AI platform, we will be able to combine two cutting edge technologies to provide unmatched possibility.

A second partnership with MeFy will aid us in growing global data sets in developing economies, helping us secure a more diverse database than any other on Earth. This partnership will be particularly valuable in India, where we will working directly with hospitals to gather data. This is just one step in our extended mission to provide access to the ability to draw data within underrepresented communities, contributing directly to our creation of a database that will provide answers not just for those who are already being researched but for communities who until now were criminally under-researched. Combined, the two platforms produce an expanded data hub that can better inform the pharmaceutical, medical and health insurance communities to produce the most targeted, effective patient treatments.

As 2018 nears its final stretch, Shivom is focused on developing their genomic medicine technology to help connect areas that have until now been disconnected and to support the medical research community in creating life-saving breakthroughs. At the end of the day, it’s people and patients who will benefit.

September Sickle Cell Awareness Campaign — Plus more updates about our Diabetes work in India

September Sickle Cell Awareness Campaign India
September Sickle Cell Awareness Campaign India

Following the announcement of our partnership with eMQT, Shivom asks the community to take a moment to reflect on the devastating genetic disorder Sickle Cell Disease (SCD)

SCD is a blood disease and particularly common in people with an African or Caribbean family background. Patients with SCD produce irregular shaped red blood cells that can cause complications because they don’t live as long as healthy blood cells and can’t carry enough oxygen around the body. Due to their shape, these blood cells can get stuck inside smaller blood vessels. This keeps blood from flowing and can cause pain and severe damage to parts of the body, ultimately leading to a reduced life expectancy.

We are inviting patients, physicians, and researchers to share their experiences with SCD on our social media channels.

Follow us, tweet at us @ProjectShivom, and use the hashtag #SickleCellAwareness OR you can send us your story to

Read more about our work with SCD and our partnership with eMQT here

Moving Forward with Diabetes Pilot in India

Moving Forward with Diabetes Pilot in India

Towards the end of September our CEO, Henry Ines, and our Co-Founder and CSO, Dr. Axel Schumacher will again head to India to begin our Type II diabetes (T2D) pilot study in the state of Andhra Pradesh, located in the south-eastern part of the subcontinent. Together with our Indian partners, including a diagnostics clinic and local doctors, we will initiate the collection of DNA samples from diabetes patients and matched control subjects. Among others, the work will also involve setting up recruitment, sample logistics, educational programs, and standard operating procedures for the pilot and further projects. identification of biomarkers for accurate classification of patient subgroupsOur pilot program serves to bring precision medicine studies to the next era. The study will not only aim at finding genotypes that are specific to Indian sub populations but help diagnose and treat the disease. Collected data will help to further our blockchain platform, provide a proof of concept of assigning digital identities for the local population, and provide data ownership to study participants. By using state-of-the-art AI algorithms, Shivom and our partners will work towards the identification of biomarkers for accurate classification of patient subgroups and diabetes management apps within our platform.


What’s New with Our Platform?

We are thrilled by the high-interest shown by our community to test one of our first modules. Please stay tuned for more information regarding the release date and details for logging into the test module.

We look forward to providing the community with more updates next month and hearing your SCD stories.

As always, we thank you for your continued support and dedication.

Shivom Team

Exciting Changes within SHIVOM’s Management Team!

Exciting Changes within SHIVOM’s Management Team
Exciting Changes within SHIVOM’s Management Team

Here at OMIX Ventures Pvt Ltd. Project SHIVOM (Token Ticker: OMX), now post-ICO and focused on execution and growth, the leadership team has decided to make some significant management changes to ensure efficient execution and platform roll out.

We’re thrilled to announce that Henry Ines has been named as Chief Executive Officer of the global blockchain-based genomics and precision medicine services company.

Henry has deep experience and knowledge of strategic development, corporate finance, startup scaling and execution based on decades of professional experience to include years as a VC, while working in Silicon Valley and Asia as a partner at Draper Dragon Fund, DFJ Dragon Fund and DragonVenture and focusing on early stage investments in frontier technologies to include FinTech & blockchain, artificial intelligence and VR/AR. Henry continues to serve on the advisory board of multiple Blockchain and Silicon Valley tech startups and serves as a mentor to leading incubators and accelerators. Henry is also a lecturer at the Nanyang Technopreneurship Center (NTC), Nanyang Technological University (NTU) and is a Senior Member of the World Education Blockchain Association (WEBA) in Singapore. He began his career at McNeil Consumer Products Company, a subsidiary of Johnson & Johnson, and as a management consultant to Fortune 100 companies while working at Price Waterhouse LLP. Henry holds a BS in Finance from Pennsylvania State University in University Park, PA and an MBA from Duke University Fuqua School of Business in Durham, NC.

“As we enter the Post-ICO phase, I am thrilled to lead the team at SHIVOM, focusing on tackling the many problems associated with the global healthcare system through genomics. The current healthcare system continues to be inefficient and face considerable challenges. Patients’ data continues to not be secure as is evident with the recent disclosures of data breaches. Additionally, many of the prevailing genetics companies and healthcare intermediaries continue to advance business models and practices that are not necessarily consistent with and in the best interests of donors or patients. We are looking forward to being able to empower individuals by providing significant insights into their genomes and health, tools for better managing and determining who has access to personal healthcare data, and enabling individuals to better manage their health and wellness through SHIVOM’s secure blockchain-based technology platform and healthcare ecosystem.”

Dr. Axel Schumacher, company co-founder who has been CEO up to now will continue as Chief Scientific Officer, leveraging his extensive research background and expertise in genomics and precision medicine. Additionally, Dr. Natalie Pankova moves into the role of Chief Operating Officer, and will lead operations out of our London office, leveraging her background in startup operations, business development and R&D, as well as her deep involvement in the global healthcare blockchain community. We believe these roles reflect the most direct path to success for our company, our supporters, and our vision.

SHIVOM cannot wait to build the world’s largest genomics datahub to help support clinical trials, advance research and development and drug discovery process globally, and ultimately work to democratize genomics for all. It is our mission to not only maintain a secure and safe platform for our users and web-market players, but also address the genomic-based complex and rare diseases such as diabetes utilizing advanced technologies such as blockchain and artificial intelligence.

We have a very special team that is dedicated to SHIVOM’s mission and working hard to execute in accordance with the company’s roadmap and growth strategy. As a startup, we must be nimble, iterate as needed and quickly respond to dynamic and evolving conditions. We are confident about our new changes, and keen to work together in new capacities to more effectively execute on our vision and take the company to new heights.

Thank you for your continued support as we enter this new wave of development, and stay tuned into our media outlets for more exciting news coming soon!

Shivom Management Team

Shivom Partners With SingularityNET For Strengthening Genomics Medical Research and Advanced…

As a step forward towards building the world’s most extensive database of DNA records, we have partnered with SingularityNETso, the pioneers of innovations in AI and deep learning. Popular for being one of the contributors to the development of the world’s first Humanoid ‘Sophia’, SingularityNET’s AI will strengthen our toolset for providing personalized medical analytics by integrating with Shivom’s decentralized network capability.

SingularityNET’s decentralized AI network provides an open market for anyone to develop, share and monetize AI services and algorithms. This is a lucrative alliance for communities in both entities to go full throttle and unlatch optimal benefits.

Shivom Partners With SingularityNET For Strengthening Genomics Medical Research and Advanced

Going Ahead — Strengthening Shivom For The Long Term

Post successful integration of the two networks, AI agents on the SingularityNET’s decentralized platform can request biological datasets from Shivom, to execute certain analytical tasks. Similarly, a Shivom customer can seek AI analytics to be performed on the genomics data uploaded.

Such synergized networks will help boost medical professionals, researchers and the customers needs with a more accurate and more hassle-free understanding of one’s health analysis bypassing impediments in data flow necessary for this type of analysis to take place via 3rd party services.

The cross-disciplinary data sharing amidst the two networks will be driven by automated conversion between the Shivom Tokens and SingularityNET’s AGI Tokens. Followed by deep encryption of datasets in transaction coupled with cross-network reputation management, the fundamental principle of the Blockchain towards data privacy is assured.

” Shivom Co-Founder and CEO, Dr. Axel Schumacher, elaborated on the partnership and said “We are excited to work with SingularityNET. AI approaches are well suited to model the complex dependencies in the regulatory landscape of our genome and can help to predict an individual’s probability of developing certain diseases. Such information should be made actionable. As such, we are confident that AI will play a central role in our platform for achieving greater depth in the interpretation of genetic information such as how an individual’s genes may impact their lifestyle decisions or help their healthcare providers to design of potential therapies.”

SingularityNET CEO, Dr. Ben Goertzel pitched in saying, “ “We are enthused to have the opportunity to support Shivom’s vision of next-era genomic research. The Shivom vision synergizes beautifully with the SingularityNET vision; the integration of Shivom’s technology, tools, and data with our SingularityNET mind-network will add more scope and intelligence into the field of personalized medical analytics.I. Together, we can achieve great things for medical science by utilizing high-quality datasets, SingularityNET’s algorithms and customer base for biomedical analytics services, and Shivom’s genomics-focused software.”

What’s Ahead?

In our mission to unlock the data stored in billions of genetic codes across the globe, this alliance is a breakthrough move. As partners, we really look forward to redefining medical research as we usher in a new era of healthcare and maximize the capabilities of Shivom’s genetic data storage and analysis platform.

Shivom is pushing policies for reimbursement of genetic testing

One of the main challenges for the development and implementation of precision medicine is the lack of reimbursement for genetic tests in most countries. There are many examples of clinically useful information available through newly developed genetic tests. While some health insurance plans in the US cover the cost of genetic testing when recommended by a physician, other forms of genome sequencing are usually not included, especially not in the EU and most Asian countries.

Without question, genomic medicine will revolutionize clinical practice in the coming years. As such, it is essential that genetic testing reimbursement processes are improved, particularly for whole-genome sequencing. To change the status-quo, recently, Shivom, together with other entrepreneurs from all over the EU including the Netherlands, Italy, France, Germany, UK, and Hungary joined forces with experts from the healthcare industry, including insurers and policymakers during a policy perspective meeting of the European Commission in The Hague/Netherlands.

A hot topic of this policy perspective meeting was the reimbursement of genetic tests because uncertain or inadequate reimbursement by public and private payers of genetic tests creates one of the most significant barriers to the development and adoption of precision medicine. We at Shivom think that genome sequencing, in general, should be subject to reimbursement, including direct to consumer (DTC) genetic testing, which enables consumers or patients to access their genetic information directly from a testing company.

Shivom is pushing policies for reimbursement of genetic testing

Dr. Axel Schumacher, CEO of Shivom: “To have access to your DNA sequence may be necessary for many reasons, including for predicting individual predispositions to diseases or conditions, or for preventive, therapeutic, reproductive, or life planning measures. Lack of a positive reimbursement decision disincentivizes patient participation and creates a barrier to the use of modern genomic medicine by authorizing clinicians and patients. As long as a whole genome sequencing test is scientifically valid (of high quality), it should be reimbursed; even more so because it has to be done only once in a person’s life.”

At Shivom, we strongly believe that now is the time to foster a new era of precision medicine through policy changes that empower patients, researchers and healthcare providers to work together toward development of personalized care.